All In Biotech

NDA 202236 · Mylan Speciality Lp

Dymista

Azelastine Hydrochloride, Fluticasone Propionate · Nasal

Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

May 1, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

62

23 Phase 3, 1 recruiting

FAERS reports

4,131

2,443 serious, 65 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2024.

Azelastine hydrochloride and fluticasone propionate nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. Azelastine hydrochloride and fluticasone propionate nasal spray contains an H 1 -receptor antagonist and a corticosteroid, and is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. ( 1 )

Mechanism: Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Azelastine hydrochloride and fluticasone propionate nasal spray contains both azelastine hydrochloride and fluticasone propionate; therefore, the mechanisms of actions described below for the individual components apply to azelastine hydrochloride and fluticasone propionate nasal spray. These drugs represent two different classes of medications (histamine H 1 -receptor antagonist and synthetic corticosteroid). Azelastine Hydrochloride Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H 1 -receptor...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DYMISTA · AZELASTINE HYDROCHLORIDE 0.137MG/SPRAY; FLUTICASONE PROPIONATE 0.05MG/SPRAY · SPRAY, METERED, NASAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Azelastine" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea328
  • drug ineffective311
  • fatigue287
  • headache278
  • asthma267
  • cough256
  • nausea241
  • sinusitis204
  • pneumonia202
  • dizziness180
  • off label use176
  • diarrhoea158

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20125
201319
201472
2015556
2016444
2017334
2018366
2019395
2020390
2021272
2022257
2023254
2024321
2025266
2026179

Recalls

2 FDA enforcement reports for this application.

  • Feb 1, 2019 · Class II · Terminated

    Defective Container: Potential for broken glass in the neck area of the glass bottles.

  • Jul 25, 2018 · Class II · Terminated

    Presence of foreign substance: Potential for glass in the neck area of the glass bottles.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dymista (Azelastine/Fluticasone)

2024 spending

$604K

Beneficiaries

816

2,117 claims

Per beneficiary

$741

$8.63 per unit

View as table
YearSpending
2020$9,622,713
2021$2,743,947
2022$1,901,225
2023$486,687
2024$604,311

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 190 on PubMed

Sponsor: Mylan Speciality Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.